

Resolution



of the Resolution of the Federal Joint Committee (G-BA)
on an Amendment of the Pharmaceuticals Directive
(AM-RL):

Annex XII - Benefit Assessment of Medicinal Products
with New Active Ingredients according to Section 35a
SGB V

Tezacaftor/Ivacaftor (new therapeutic indication: cystic
fibrosis, combination therapy with Ivacaftor in patients
aged 6 < 12 years (homozygous or F508del-Mutation))

of 20 May 2021

At its meeting on 20 May 2021, the Federal Joint Committee (G-BA) resolved to amend the
Pharmaceuticals Directive, (AM-RL) in the version dated 18 December 2008/22 January 2009
(Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended on DD Month YYYY
(Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

- I. **In Annex XII, the following information shall be added after No. 4 to the information
on the benefit assessment of tezacaftor/ivacaftor in accordance with the resolution
of 17 December 2020:**

Tezacaftor/ivacaftor

Resolution of: 20 May 2021

Entry into force on: 20 May 2021

BAnz AT DD MM YYYY Bx

New therapeutic indication (according to the marketing authorisation of 25 November 2020):

Symkevi is used as a combination treatment with ivacaftor tablets for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who are homozygous for the F508del-Mutation or heterozygous for the F508del-Mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR gene): P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G and 3849+10kbC→T.

Therapeutic indication of the resolution (resolution of 20 May 2021):

Symkevi is used as a combination treatment with ivacaftor tablets for the treatment of cystic fibrosis (CF) in children 6 years < 12 years of age who are homozygous for the F508del-Mutation.

1. Additional benefit of the medicinal product in relation to the appropriate comparator therapy

Children with cystic fibrosis aged 6 < 12 years who are homozygous for the F508del-Mutation.

Appropriate comparator therapy:

Lumacaftor/Ivacaftor

Extent and probability of the additional benefit of tezacaftor/ivacaftor in combination with ivacaftor compared to the appropriate comparator therapy:

An additional benefit is not proven.

Study results according to endpoints:

Children with cystic fibrosis aged 6 < 12 years who are homozygous for the F508del-Mutation.

No adequate data are available to allow an assessment of the additional benefit.

Summary of results for relevant clinical endpoints

Endpoint category	Direction of effect/ Risk of bias	Summary
Mortality	n.c.	There are no evaluable data.
Morbidity	n.c.	There are no evaluable data.
Health-related quality of life	n.c.	There are no evaluable data.
Side effects	n.c.	There are no evaluable data.
<p>Explanations:</p> <p>↑: statistically significant and relevant positive effect with low/unclear reliability of data</p> <p>↓: statistically significant and relevant negative effect with low/unclear reliability of data</p> <p>↑↑: statistically significant and relevant positive effect with high reliability of data</p> <p>↓↓: statistically significant and relevant negative effect with high reliability of data</p> <p>↔: no statistically significant or relevant difference</p> <p>∅: There is no usable data for the benefit assessment.</p> <p>n.a.: not assessable</p>		

2. Number of patients or demarcation of patient groups eligible for treatment

Children with cystic fibrosis aged 6 < 12 years who are homozygous for the F508del-Mutation.

approx. 470 patients

3. Requirements for a quality-assured application

The requirements in the product information are to be taken into account. The European Medicines Agency (EMA) provides the contents of the product information (summary of product characteristics, SmPC) for Symkevi (active ingredient: tezacaftor/ivacaftor) at the following publicly accessible link (last access: 1 April 2021):

https://www.ema.europa.eu/en/documents/product-information/symkevi-epar-product-information_de.pdf

Treatment with tezacaftor/ivacaftor should only be initiated and monitored by doctors experienced in treating patients with cystic fibrosis.

4. Treatment costs

Annual treatment costs:

Name of therapy	Annual treatment costs/patient
Medicinal product to be assessed:	
Tezacaftor/ivacaftor	€ 65,032.44
+ Ivacaftor ¹	€ 100,977.84 – € 101,032.65
Total:	€ 166,010.28 – € 166,065.09
Appropriate comparator therapy:	
Lumacaftor/Ivacaftor	€ 148,415.91

Costs after deduction of statutory rebates (LAUER-TAXE®, as last revised: 1 May 2021).

Costs for additionally required SHI services: not applicable

II. The resolution will enter into force on the day of its publication on the internet on the G-BA website on 20 May 2021.

The justification for this resolution will be published on the G-BA website at www.g-ba.de.

Berlin, 20 May 2021

Federal Joint Committee in accordance with Section 91 SGB V The chairman

Prof. Hecken

¹ The range of ivacaftor is based on different doses depending on body weight (< 30 kg bw or ≥ 30 kg bw, respectively)